Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Nov 20, 2020
Deals
After three-target Lilly deal, Precision BioSciences hunting for more partnerships
With $135M up front, Lilly deal unlocks value from biotech’s ARCUS genome-editing tech
Read More
BioCentury
|
Jun 27, 2020
Deals
Who’ll buy uniQure now?
Even without its lead hemophilia program, the gene therapy company could make for an attractive takeout target
Read More
BioCentury
|
Sep 7, 2019
Product Development
Regeneron’s evinacumab data could make it the therapy of choice in HoFH
Better efficacy and safety could make Regeneron’s evinacumab the standard of care for HoFH
Read More
BioCentury
|
Jun 18, 2019
Company News
Latest twist in uniQure’s tale: possible sale
Read More
BioCentury
|
Jun 17, 2019
Company News
Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model
Read More
BioCentury
|
Jul 20, 2018
Regulation
FDA’s positive reinforcement
How FDA’s gene therapy guidances reinforce the paths of the most advanced candidates
Read More
BioCentury
|
Jul 10, 2018
Distillery Techniques
Biomarkers; other
Read More
BioCentury
|
May 11, 2018
Clinical News
FDA panel backs volanesorsen approval
Read More
BioCentury
|
May 10, 2018
Company News
FDA panel backs volanesorsen approval
Read More
BioCentury
|
May 8, 2018
Company News
FDA reviewers question Akcea candidate's safety
Read More
Items per page:
10
1 - 10 of 140